Φορτώνει......
Variable CD52 Expression in Mature T Cell and NK Cell Malignancies: Implications for Alemtuzumab Therapy
The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T-cell malignancies. To assess the suitability of alemtuzumab therapy we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/NK cell neoplas...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | , , , , , , , |
---|---|
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
2009
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3487105/ https://ncbi.nlm.nih.gov/pubmed/19236377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07606.x |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|